FDA Airs Safety Concerns About Merck Insomnia Drug

Law360, New York (May 20, 2013, 7:41 PM EDT) -- The U.S. Food and Drug Administration on Monday released a clinical study of Merck & Co. Inc. insomnia drug suvorexant revealing some troubling side effects, including suicidal behavior and impaired driving performance.

In a review published two days ahead of a scheduled public meeting to discuss the drug, the FDA concluded that excessive drowsiness is the most prominent side effect and was strong enough to impact driving safety.

The agency also said the drug seems to increase the risk of suicidal thoughts and behavior, finding such...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.